
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
An Overview of Integrated Managed Careover 27 years ago
Community-Acquired Pneumonia: Approaches within Managed Careover 27 years ago
Selected Abstractsover 27 years ago
Bibliography





